Overview

DIABGAD - Trial to Preserve Insulin Secretion in Type 1 Diabetes Using GAD-Alum (Diamyd) in Combination With Vitamin D and Ibuprofen

Status:
Completed

Trial end date:
2017-03-01

Target enrollment:

Participant gender:

Summary

The objectives of this study is to - evaluate the safety and influence of treatment with GAD-Alum (Diamyd) combined with Vitamin D and Ibuprofen on preservation of residual insulin secretion in recently diagnosed Type 1 Diabetes - evaluate how the above mentioned treatments influence the immune system of the subjects and interact with any viral infections - evaluate the safety and influence of treatment with double dose of GAD-Alum (Diamyd) plus Vitamin D on the immune system, viral infections, and on preservation of residual insulin secretion in recently diagnosed Type 1 Diabetes

Phase:

Phase 2

Details

Lead Sponsor:

Johnny Ludvigsson

Collaborators:

Diamyd Medical AB
Sahlgrenska University Hospital, Sweden
Swedish Child Diabetes Foundation
The Research Council of South East Sweden (FORSS)

Treatments:

Aluminum sulfate
Ergocalciferols
Ibuprofen
Insulin
Vitamin D
Vitamins